<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36999036</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>03</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>14</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Cyclophosphamide-induced seizures in a patient with neuropsychiatric systemic lupus erythematosus (NPSLE): A case report.</ArticleTitle><Pagination><StartPage>1122629</StartPage><MedlinePgn>1122629</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1122629</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2023.1122629</ELocationID><Abstract><AbstractText>Seizures are life-threatening complications of neuropsychiatric systemic lupus erythematosus (NPSLE) and are often associated with poor outcomes. Cyclophosphamide immunotherapy is the mainstay of NPSLE treatment. We report the unique case of a patient with NPSLE who developed seizures soon after her first and second doses of low-dose cyclophosphamide. The exact pathophysiological mechanism underlying cyclophosphamide-induced seizures is not well understood. However, this unusual drug-associated side effect of cyclophosphamide is thought to be due to the drug's unique pharmacology. Clinicians should be aware of this complication to make a correct diagnosis and adjust the immunosuppressive regimens very carefully.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Zhang, Shi, Zhang, Wu and Jiang.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Lingshu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Integrated Traditional Chinese and Western Medicine, The Ninth People's Hospital of Chongqing, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jingyao</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Core Facilities of West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Internal Medicine Department, Xihua University Hospital, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Integrated Traditional Chinese and Western Medicine, The Ninth People's Hospital of Chongqing, Chongqing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>8N3DW7272P</RegistryNumber><NameOfSubstance UI="D003520">Cyclophosphamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020945" MajorTopicYN="Y">Lupus Vasculitis, Central Nervous System</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003520" MajorTopicYN="N">Cyclophosphamide</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012640" MajorTopicYN="N">Seizures</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cyclophosphamide</Keyword><Keyword MajorTopicYN="N">immunotherapy</Keyword><Keyword MajorTopicYN="N">neuropsychiatric lupus erythematosus</Keyword><Keyword MajorTopicYN="N">seizure</Keyword><Keyword MajorTopicYN="N">side effect analysis</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>3</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>31</Day><Hour>2</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36999036</ArticleId><ArticleId IdType="pmc">PMC10049787</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2023.1122629</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>The American college of rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum (1999) 42(4):599&#x2013;608. doi:&#xa0;10.1002/1529-0131(199904)42:4&lt;599::AID-ANR2&gt;3.0.CO;2-F</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1529-0131(199904)42:4&lt;599::AID-ANR2&gt;3.0.CO;2-F</ArticleId><ArticleId IdType="pubmed">10211873</ArticleId></ArticleIdList></Reference><Reference><Citation>Unterman A, Nolte JE, Boaz M, Abady M, Shoenfeld Y, Zandman-Goddard G. Neuropsychiatric syndromes in systemic lupus erythematosus: A meta-analysis. Semin Arthritis Rheum (2011) 41(1):1&#x2013;11. doi:&#xa0;10.1016/j.semarthrit.2010.08.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2010.08.001</ArticleId><ArticleId IdType="pubmed">20965549</ArticleId></ArticleIdList></Reference><Reference><Citation>Kivity S, Agmon-Levin N, Zandman-Goddard G, Chapman J, Shoenfeld Y. Neuropsychiatric lupus: A mosaic of clinical presentations. BMC Med (2015) 13:43. doi:&#xa0;10.1186/s12916-015-0269-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-015-0269-8</ArticleId><ArticleId IdType="pmc">PMC4349748</ArticleId><ArticleId IdType="pubmed">25858312</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanly JG, Urowitz MB, Su L, Bae SC, Gordon C, Wallace DJ, et al. . Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. Ann Rheum Dis (2010) 69(3):529&#x2013;35. doi:&#xa0;10.1136/ard.2008.106351</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2008.106351</ArticleId><ArticleId IdType="pmc">PMC2929162</ArticleId><ArticleId IdType="pubmed">19359262</ArticleId></ArticleIdList></Reference><Reference><Citation>Devinsky O, Schein A, Najjar S. Epilepsy associated with systemic autoimmune disorders. Epilepsy Curr (2013) 13(2):62&#x2013;8. doi:&#xa0;10.5698/1535-7597-13.2.62</Citation><ArticleIdList><ArticleId IdType="doi">10.5698/1535-7597-13.2.62</ArticleId><ArticleId IdType="pmc">PMC3639560</ArticleId><ArticleId IdType="pubmed">23646005</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S, Li M, Zhang L, Wang Z, Wang Q, You H, et al. . Clinical features and outcomes of neuropsychiatric systemic lupus erythematosus in China. J Immunol Res (2021) 2021:1349042. doi:&#xa0;10.1155/2021/1349042</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/1349042</ArticleId><ArticleId IdType="pmc">PMC7834780</ArticleId><ArticleId IdType="pubmed">33532504</ArticleId></ArticleIdList></Reference><Reference><Citation>Emadi A, Jones RJ, Brodsky RA. Cyclophosphamide and cancer: Golden anniversary. Nat Rev Clin Oncol (2009) 6(11):638&#x2013;47. doi:&#xa0;10.1038/nrclinonc.2009.146</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrclinonc.2009.146</ArticleId><ArticleId IdType="pubmed">19786984</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeltsch-David H, Muller S. Neuropsychiatric systemic lupus erythematosus: Pathogenesis and biomarkers. Nat Rev Neurol (2014) 10(10):579&#x2013;96. doi:&#xa0;10.1038/nrneurol.2014.148</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2014.148</ArticleId><ArticleId IdType="pubmed">25201240</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrion-Barbera I, Salman-Monte TC, Vilchez-Oya F, Monfort J. Neuropsychiatric involvement in systemic lupus erythematosus: A review. Autoimmun Rev (2021) 20(4):102780. doi:&#xa0;10.1016/j.autrev.2021.102780</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2021.102780</ArticleId><ArticleId IdType="pubmed">33609799</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanly JG, Kozora E, Beyea SD, Birnbaum J. Review: Nervous system disease in systemic lupus erythematosus: Current status and future directions. Arthritis Rheumatol (2019) 71(1):33&#x2013;42. doi:&#xa0;10.1002/art.40591</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40591</ArticleId><ArticleId IdType="pubmed">29927108</ArticleId></ArticleIdList></Reference><Reference><Citation>Postal M, Lapa AT, Reis F, Rittner L, Appenzeller S. Magnetic resonance imaging in neuropsychiatric systemic lupus erythematosus: Current state of the art and novel approaches. Lupus (2017) 26(5):517&#x2013;21. doi:&#xa0;10.1177/0961203317691373</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203317691373</ArticleId><ArticleId IdType="pubmed">28394232</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarbu N, Toledano P, Calvo A, Roura E, Sarbu MI, Espinosa G, et al. . Advanced MRI techniques: Biomarkers in neuropsychiatric lupus. Lupus (2017) 26(5):510&#x2013;6. doi:&#xa0;10.1177/0961203316674820</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203316674820</ArticleId><ArticleId IdType="pubmed">28394230</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackay M, Tang CC, Vo A. Advanced neuroimaging in neuropsychiatric systemic lupus erythematosus. Curr Opin Neurol (2020) 33(3):353&#x2013;61. doi:&#xa0;10.1097/WCO.0000000000000822</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000822</ArticleId><ArticleId IdType="pmc">PMC7259387</ArticleId><ArticleId IdType="pubmed">32349105</ArticleId></ArticleIdList></Reference><Reference><Citation>Stojanovich L, Stojanovich R, Kostich V, Dzjolich E. Neuropsychiatric lupus favourable response to low dose i.v. cyclophosphamide and prednisolone (pilot study). Lupus (2003) 12(1):3&#x2013;7. doi:&#xa0;10.1191/0961203303lu251oa</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/0961203303lu251oa</ArticleId><ArticleId IdType="pubmed">12587819</ArticleId></ArticleIdList></Reference><Reference><Citation>Barile-Fabris L, Ariza-Andraca R, Olguin-Ortega L, Jara LJ, Fraga-Mouret A, Miranda-Limon JM, et al. . Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis (2005) 64(4):620&#x2013;5. doi:&#xa0;10.1136/ard.2004.025528</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2004.025528</ArticleId><ArticleId IdType="pmc">PMC1755456</ArticleId><ArticleId IdType="pubmed">15769918</ArticleId></ArticleIdList></Reference><Reference><Citation>Papachristos DA, Oon S, Hanly JG, Nikpour M. Management of inflammatory neurologic and psychiatric manifestations of systemic lupus erythematosus: A systematic review. Semin Arthritis Rheum (2021) 51(1):49&#x2013;71. doi:&#xa0;10.1016/j.semarthrit.2020.12.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2020.12.004</ArticleId><ArticleId IdType="pubmed">33360230</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold H, Bourseaux F, Brock N. Chemotherapeutic action of a cyclic nitrogen mustard phosphamide ester (B 518-ASTA) in experimental tumours of the rat. Nature (1958) 181(4613):931. doi:&#xa0;10.1038/181931a0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/181931a0</ArticleId><ArticleId IdType="pubmed">13526741</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahlmann M, Hempel G. The effect of cyclophosphamide on the immune system: Implications for clinical cancer therapy. Cancer Chemother Pharmacol (2016) 78(4):661&#x2013;71. doi:&#xa0;10.1007/s00280-016-3152-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00280-016-3152-1</ArticleId><ArticleId IdType="pubmed">27646791</ArticleId></ArticleIdList></Reference><Reference><Citation>Dan D, Fischer R, Adler S, Forger F, Villiger PM. Cyclophosphamide: As bad as its reputation? long-term single centre experience of cyclophosphamide side effects in the treatment of systemic autoimmune diseases. Swiss Med Wkly (2014) 144:w14030. doi:&#xa0;10.4414/smw.2014.14030</Citation><ArticleIdList><ArticleId IdType="doi">10.4414/smw.2014.14030</ArticleId><ArticleId IdType="pubmed">25341028</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y, Kwak J, Jung S, Lee S, Jang HN, Cho HS, et al. . Oral cyclophosphamide-induced posterior reversible encephalopathy syndrome in a patient with ANCA-associated vasculitis: A case report. World J Clin cases (2021) 9(21):6130&#x2013;7. doi:&#xa0;10.12998/wjcc.v9.i21.6130</Citation><ArticleIdList><ArticleId IdType="doi">10.12998/wjcc.v9.i21.6130</ArticleId><ArticleId IdType="pmc">PMC8316926</ArticleId><ArticleId IdType="pubmed">34368335</ArticleId></ArticleIdList></Reference><Reference><Citation>Jabrane M, Ait Lahcen Z, Fadili W, Laouad I. A case of PRES in an active lupus nephritis patient after treatment of corticosteroid and cyclophosphamide. Rheumatol Int (2015) 35(5):935&#x2013;8. doi:&#xa0;10.1007/s00296-014-3173-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-014-3173-1</ArticleId><ArticleId IdType="pubmed">25387825</ArticleId></ArticleIdList></Reference><Reference><Citation>Abenza-Abildua MJ, Fuentes B, Diaz D, Royo A, Olea T, Aguilar-Amat MJ, et al. . Cyclophosphamide-induced reversible posterior leukoencephalopathy syndrome. BMJ Case Rep (2009) 2009. doi:&#xa0;10.1136/bcr.07.2008.0467</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bcr.07.2008.0467</ArticleId><ArticleId IdType="pmc">PMC3027326</ArticleId><ArticleId IdType="pubmed">21686794</ArticleId></ArticleIdList></Reference><Reference><Citation>Cha B, Kim DY, Jang H, Hwang SD, Choi HJ, Kim MJ. Unusual case of posterior reversible encephalopathy syndrome in a patient with anti-glomerular basement membrane antibody glomerulonephritis: A case report and review of the literature. Electrolyte Blood Press (2017) 15(1):12&#x2013;6. doi:&#xa0;10.5049/EBP.2017.15.1.12</Citation><ArticleIdList><ArticleId IdType="doi">10.5049/EBP.2017.15.1.12</ArticleId><ArticleId IdType="pmc">PMC5641497</ArticleId><ArticleId IdType="pubmed">29042902</ArticleId></ArticleIdList></Reference><Reference><Citation>Foong AL, Grindrod KA, Patel T, Kellar J. Demystifying serotonin syndrome (or serotonin toxicity). Can Fam Phys (2018) 64(10):720&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6184959</ArticleId><ArticleId IdType="pubmed">30315014</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill T, Coupland C, Morriss R, Arthur A, Moore M, Hippisley-Cox J. Antidepressant use and risk of epilepsy and seizures in people aged 20 to 64 years: Cohort study using a primary care database. BMC Psychiatry (2015) 15:315. doi:&#xa0;10.1186/s12888-015-0701-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12888-015-0701-9</ArticleId><ArticleId IdType="pmc">PMC4683813</ArticleId><ArticleId IdType="pubmed">26678837</ArticleId></ArticleIdList></Reference><Reference><Citation>Minami M, Ogawa T, Endo T, Hamaue N, Hirafuji M, Yoshioka M, et al. . Cyclophosphamide increases 5-hydroxytryptamine release from the isolated ileum of the rat. Res Commun Mol Pathol Pharmacol (1997) 97(1):13&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">9507564</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu B, Su M, Tang S, Zhou X, Zhan H, Yang F, et al. . Spinal astrocytic activation contributes to mechanical allodynia in a rat model of cyclophosphamide-induced cystitis. Mol Pain (2016) 12. doi:&#xa0;10.1177/1744806916674479</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1744806916674479</ArticleId><ArticleId IdType="pmc">PMC5117243</ArticleId><ArticleId IdType="pubmed">27852964</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker M, Markman M, Niu J. Cyclophosphamide-induced severe acute hyponatremic encephalopathy in patients with breast cancer: Report of two cases. Case Rep Oncol (2014) 7(2):550&#x2013;4. doi:&#xa0;10.1159/000365832</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000365832</ArticleId><ArticleId IdType="pmc">PMC4164106</ArticleId><ArticleId IdType="pubmed">25232325</ArticleId></ArticleIdList></Reference><Reference><Citation>Parikh S, Pettit L, AbdelGadir H. Severe hyponatraemia in two patients with breast cancer caused by low-dose cyclophosphamide and precipitated by aprepitant. BMJ Case Rep (2022) 15(3). doi:&#xa0;10.1136/bcr-2021-248408</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bcr-2021-248408</ArticleId><ArticleId IdType="pmc">PMC8943731</ArticleId><ArticleId IdType="pubmed">35318203</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>